What’s new in ovarian hyperstimulation

Abstract

Comparative outcomes of ovarian stimulation with minimal and combination therapy were presented at the 11th World Congress on In Vitro Fertilisation and Human Reproductive Genetics [ Sydney, Australia; May 1999 ]. In one study, low-dose recombinant follicle-stimulating hormone (FSH) was used in the mid-follicular phase and combined with a gonadotropin-releasing hormone (GnRH) antagonist to prevent luteinising hormone (LH) surge. In another, recombinant FSH therapy alone was compared with a combination of FSH plus recombinant LH in patients who had been downregulated with a low-dose luteal GnRH agonist (leuprorelin).